GOG-0195 trial

The GOG-0195 trial was a clinical study investigating whether adding a new targeted drug called combination chemotherapy improves outcomes for women with advanced ovarian cancer. Participants received standard treatment with or without the experimental drug to see if the combination led to longer periods without disease progression and better survival rates. The trial aimed to determine if this new approach could enhance current therapies and provide better options for managing advanced ovarian cancer.